Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials

References

• Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19
   PubMed Web of Science ®Google Scholar
• Jassem J, Carroll C, Ward SE, et al. The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review. Eur J Canc 2009;45:2749-58
   PubMed Web of Science ®Google Scholar
• Silvestris N, Cinieri S, LaTorre I, et al. Role of gemcitabine in metastatic breast cancer patients: a short review. Breast 2008;17:220-6
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7
   PubMed Web of Science ®Google Scholar
• Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753-60
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-17
   PubMedGoogle Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16
   PubMed Web of Science ®Google Scholar
• Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009;115:87-99
   PubMed Web of Science ®Google Scholar
• Tomova A, Bartsch R, Brodowicz T, et al. Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG). Breast Cancer Res Treat 2010;119:169-76
   PubMed Web of Science ®Google Scholar
• Seidman AD, Brufsky A, Ansari RH, et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol 2010;22:1094-101
   PubMed Web of Science ®Google Scholar
• Papadimitriou CA, Kalofonos H, Zagouri F, et al. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. Oncology 2009;77:212-16
   PubMed Web of Science ®Google Scholar
• Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005;16:899-908
   PubMed Web of Science ®Google Scholar
• Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European cooperative oncology group international, multicenter, prospective, randomized phase III trial. J Clin Oncol 2005;23:1401-8
   PubMed Web of Science ®Google Scholar
• Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-25
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7
   PubMed Web of Science ®Google Scholar
• Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753-60
   PubMed Web of Science ®Google Scholar
• Joensuu H, Sailas L, Alanko T, et al. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol 2009;21:968-73
   PubMed Web of Science ®Google Scholar
• Nielsen DL, Bjerre KD, Jakobsen EH, et al. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. J Clin Oncol 2011;29:4748-54
   PubMed Web of Science ®Google Scholar
• Brufsky A, Hoelzer K, Beck T, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Canc 2011;11:211-20
   PubMed Web of Science ®Google Scholar
• Pallis AG, Boukovinas I, Ardavanis A, et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 2011;23:1164-9
   PubMed Web of Science ®Google Scholar
• Fernández Y, Cueva J, Palomo AG, et al. Novel therapeutic approaches to the treatment of metastatic breast cancer. Canc Treat Rev 2010;36:33-42
   PubMed Web of Science ®Google Scholar
• Crown J, Diéras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer – report of a European expert panel. Lancet Oncol 2002;3:719-27
   PubMed Web of Science ®Google Scholar
• Belfiglio M, Fanizza C, Tinari N, et al. Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Canc Res Clin Oncol 2011;138:221-9
   PubMed Web of Science ®Google Scholar
• Qi WX, Tang LN, He AN, et al. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials. Breast 2013;22:314-19
   PubMed Web of Science ®Google Scholar